the aid library

LIST OPTIONS

Filter

8087

Sort by:

Direction:

Download (323)

View PDF (232)

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines
recommended

World Health Organization (WHO) (1992) C_WHO

Provides clinical descriptions, diagnostic guidelines, and codes for all mental and behavioural disorders commonly encountered in clinical psychiatry. The book was developed from chapter V of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (... more

Download (79)

View PDF (137)

Справочник базовойи нформации ВОЗ по психическому здоровью, правам человека и законодательству

Melvyn Freeman, Michelle Funk, Soumitra Pathare et al. World Health Organization (2005) C_WHO

В Справочнике приводятся три ключевых элемента эффективного законодательства: контекст, содержание и процесс, – другими словами, «почему», «что» и «как» должно бы... more

Download (424)

View PDF (904)

HIV and Infant Feeding in Emergencies: Operational Guidance

World Health Organization (WHO) (2018) C_WHO

The duration of breastfeeding and support from health services to improve feeding practices among mothers living with HIV
This operational guidance, developed by WHO, UNICEF and ENN, outlines the duration of breastfeeding and support from health services to improve infant feeding practices amon... more

Download (159)

View PDF (326)

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

World Health Organization (2019) C_WHO

It is estimated that more than 311 000 women die of cervical cancer each year. Of these deaths, 91% occur in low- and middle-income countries. Demographic changes and a lack of action mean that the number of deaths per year is projected to reach 460 000 by 2040.

Download (109)

View PDF (272)

WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer

World Health Organization WHO (2020) C_WHO

Globally, 311,000 women die of cervical cancer every year, 85 percent of them in resource limited regions of the world. To address this grave threat to women, the WHO made a call to action in 2018, resulting in accelerated plans to improve cervical cancer control under the elimination threshold w... more

Download (91)

View PDF (175)

Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031

World Health Organization WHO (2022) C_WHO

Draft plan

Download (67)

View PDF (761)

Behavioural and social drivers of vaccination: tools and practical guidance for achieving high uptake

World Health Organization WHO; UN Children´s Fund (2022) C_WHO

Tools and practical guidance for achieving high uptake

Download (146)

View PDF (176)

Ending the neglect to attain the sustainable development goals: a rationale for continued investment in tackling neglected tropical diseases 2021–2030

World Health Organization WHO (2022) C_WHO

This document sets out, therefore, to explain the socioeconomic value of investing in the fight against NTDs and highlights priorities for global investment attention. Our work was guided by the need not only for additional funding and funders but also for the need to understand the current funding... more

Download (135)

View PDF (129)

Ending the neglect to attain the sustainable development goals: a strategic framework for integrated control and management of skin-related neglected tropical diseases

World Health Organization WHO (2022) C_WHO

Skin-related neglected tropical diseases, or “skin NTDs”, are historically neglected because active case detection, individual case management, significant resources and intensive effort are required to control, eliminate and eradicate them. Integrated control and management of skin NTDs offers ... more

Download (51)

View PDF (324)

Marco de competencias para la rehabilitación

World Health Organization WHO (2022) C_WHO

El Marco de Competencias para la Rehabilitación (MCR) es un modelo que comunica el desempeño que se espera o al que se aspira del personal de rehabilitación en todas las profesiones, especializaciones y entornos para hacer posible una atención y una prestación de servicios de calidad. Incluy... more

Download (151)

View PDF (145)

Obstetric Fistula Strategic Plan 2022 - 2026

Government of Zambia World Health Organisation (WHO) Regional Office Africa (2023) C_WHO

Globally, over two million women live with obstetric fistula with the majority of the cases being from Africa. In low-resource settings such as Zambia, obstetric fistula (OF) is a visible indicator of gaps in maternal health care resulting in failure to provide adequate, accessible and quality m... more

Download (49)

View PDF (49)

Audited Financial Statements for the year ended 31 December 2020

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

WHO’s total revenue in 2020 was US$ 4299 million and total expenses were US$ 3561 million, resulting in a surplus of US$ 824 million, which includes finance revenue (e.g. interest and investment income) of US$ 86 million, representing increases of 38% and 15% in revenue and expenses respectively. ... more

Download (38)

View PDF (43)

Sustainable financing: report of the Working Group - Report by the Director-General

Working Group on Sustainable Financing World Health Organization (WHO) (2022) CC

The Director-General has the honour to transmit to the Seventy-fifth World Health Assembly the report of the seventh meeting of the Working Group on Sustainable Financing, which met in a hybrid format, from 25 to 27 April 2022.

Download (58)

View PDF (53)

Sustainable financing: Report by the Director-General

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

The biennium 2020–2021 has revealed more clearly than ever the need for a strong, credible and independent WHO on the world stage. The coronavirus disease (COVID-19) crisis has demonstrated the fundamental importance of the global detection, response and coordination roles that only WHO can play a... more

Download (105)

View PDF (107)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (124)

View PDF (126)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (74)

View PDF (80)

WHO Guide to conducting programme reviews for HIV, viral hepatitis and sexually transmitted infections

World Health Organization WHO (2023) C_WHO

Sound periodic programme reviews provide opportunities for countries to objectively assess progress and take corrective action to sustain or get back on track towards achieving their medium and long-term programme goals. It reflects people’s diverse needs, enables efficient use of health system re... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (125)

View PDF (95)

Clinical management of diphtheria: guideline

World Health Organization WHO (2024) C_WHO

WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO. It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen... more

Download (98)

View PDF (66)

WHO Emergency Response Framework - Internal WHO procedures - Second Edition

World Health Organization WHO (2024) C_WHO

The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore a... more

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines recommended

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines
recommended